Payment overview · 2025
General Payments
$498.07
37 reported records · 8 companies
Healthcare provider profile · identity verified
Kyle David Toti, D.O.
Allopathic & Osteopathic Physicians|Family Medicine · CEDAR HILL, MO · NPI 1669735791
Verified facts
What the public records show
CMS Open Payments records show Kyle David Toti, D.O. received $498.07 in general payments during 2025 across 37 reported records.
ABBVIE INC. accounted for 70.7% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 10 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Eliquis, Gemtesa, Vraylar.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LINZESS as an associated drug or biological on 87954 records involving 21815 distinct recipient NPIs. Public Medicare Part D data also shows 21 claims for Linzess by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 19 claims for Synthroid by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported VRAYLAR as an associated drug or biological on 377741 records involving 62704 distinct recipient NPIs. Public Medicare Part D data also shows 16 claims for Vraylar by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 34 claims for Ozempic by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 358 claims for Eliquis by this doctor in 2024.
Sumitomo Pharma America, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported GEMTESA as an associated drug or biological on 61692 records involving 22152 distinct recipient NPIs. Public Medicare Part D data also shows 81 claims for Gemtesa by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| ABBVIE INC. | Unresolved — no canonical attribution shown | $352.20 | 70.7% | 29 | 2025 |
| Abbott Laboratories | Unresolved — no canonical attribution shown | $36.78 | 7.4% | 2 | 2025 |
| Viatris Specialty LLC | Unresolved — no canonical attribution shown | $21.88 | 4.4% | 1 | 2025 |
| Sumitomo Pharma America, Inc. | Unresolved — no canonical attribution shown | $19.78 | 4.0% | 1 | 2025 |
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $19.04 | 3.8% | 1 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $18.88 | 3.8% | 1 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $15.92 | 3.2% | 1 | 2025 |
| Kowa Pharmaceuticals America, Inc. | Unresolved — no canonical attribution shown | $13.59 | 2.7% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $498.07 | 37 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| VRAYLAR Normalized: vraylar |
Drug | ABBVIE INC. | $260.44 | 26 | 2025 |
Source payment records
|
|||||
| QULIPTA Normalized: qulipta |
Drug | ABBVIE INC. | $91.76 | 3 | 2025 |
Source payment records
|
|||||
| FREESTYLE LIBRE 3 Normalized: freestyle libre 3 |
Device | Abbott Laboratories | $36.78 | 2 | 2025 |
Source payment records
|
|||||
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $33.37 | 1 | 2025 |
Source payment records
|
|||||
| YUPELRI Normalized: yupelri |
Drug | Viatris Specialty LLC | $21.88 | 1 | 2025 |
Source payment records
|
|||||
| GEMTESA Normalized: gemtesa |
Drug | Sumitomo Pharma America, Inc. | $19.78 | 1 | 2025 |
Source payment records
|
|||||
| The Cologuard Plus Collection Kit Normalized: the cologuard plus collection kit |
Device | Exact Sciences Corporation | $19.04 | 1 | 2025 |
Source payment records
|
|||||
| Wegovy Normalized: wegovy |
Drug | Novo Nordisk Inc | $18.88 | 1 | 2025 |
Source payment records
|
|||||
| ELIQUIS Normalized: eliquis |
Drug | PFIZER INC. | $15.92 | 1 | 2025 |
Source payment records
|
|||||
| ZORYVE Normalized: zoryve |
Drug | Kowa Pharmaceuticals America, Inc. | $13.59 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| ELIQUIS eliquis |
2025 | Eliquis | 2024 | 358 | exact normalized | Medicare Part D |
| GEMTESA gemtesa |
2025 | Gemtesa | 2024 | 81 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| VRAYLAR vraylar |
2025 | Vraylar | 2024 | 16 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LINZESS open payments reported associated product |
CMS Open Payments — General Payments 87954 supporting records · 21815 recipient NPIs · example record 1201352608 |
Linzess · 2024 Exact normalized brand match · 1 Part D row |
21 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
19 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | VRAYLAR open payments reported associated product |
CMS Open Payments — General Payments 377741 supporting records · 62704 recipient NPIs · example record 1201352550 |
Vraylar · 2024 Exact normalized brand match · 1 Part D row |
16 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
34 | suppressed by CMS |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
358 | 54 |
| Sumitomo Pharma America, Inc. Exact reporting entity; no affiliate inference |
2025 | GEMTESA open payments reported associated product |
CMS Open Payments — General Payments 61692 supporting records · 22152 recipient NPIs · example record 1176593503 |
Gemtesa · 2024 Exact normalized brand match · 1 Part D row |
81 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 848 | 228 |
| Lisinopril | Lisinopril | 699 | 195 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 611 | 179 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 604 | 184 |
| Amlodipine Besylate | Amlodipine Besylate | 518 | 136 |
| Pantoprazole Sodium | Pantoprazole Sodium | 465 | 112 |
| Levothyroxine Sodium | Levothyroxine Sodium | 436 | 102 |
| Alprazolam | Alprazolam | 426 | 121 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 388 | 127 |
| Gabapentin | Gabapentin | 385 | 71 |
| Eliquis | Apixaban | 358 | 54 |
| Losartan Potassium | Losartan Potassium | 352 | 100 |
| Furosemide | Furosemide | 347 | 85 |
| Trazodone Hcl | Trazodone Hcl | 339 | 84 |
| Meloxicam | Meloxicam | 308 | 83 |
| Metformin Hcl | Metformin Hcl | 296 | 68 |
| Metoprolol Succinate | Metoprolol Succinate | 279 | 74 |
| Tramadol Hcl | Tramadol Hcl | 279 | 76 |
| Potassium Chloride | Potassium Chloride | 277 | 62 |
| Omeprazole | Omeprazole | 273 | 74 |
| Duloxetine Hcl | Duloxetine Hcl | 260 | 58 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 226 | 55 |
| Tamsulosin Hcl | Tamsulosin Hcl | 224 | 56 |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 223 | 173 |
| Sertraline Hcl | Sertraline Hcl | 222 | 58 |
| Fluticasone Propionate | Fluticasone Propionate | 204 | 67 |
| Quetiapine Fumarate | Quetiapine Fumarate | 201 | 42 |
| Metoprolol Tartrate | Metoprolol Tartrate | 199 | 58 |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 183 | 53 |
| Lorazepam | Lorazepam | 180 | 38 |
| Tizanidine Hcl | Tizanidine Hcl | 171 | 67 |
| Mirtazapine | Mirtazapine | 170 | 39 |
| Metformin Hcl Er | Metformin Hcl | 168 | 54 |
| Carvedilol | Carvedilol | 158 | 36 |
| Pregabalin | Pregabalin | 157 | 31 |
| Famotidine | Famotidine | 156 | 37 |
| Montelukast Sodium | Montelukast Sodium | 156 | 41 |
| Escitalopram Oxalate | Escitalopram Oxalate | 150 | 40 |
| Hydrochlorothiazide | Hydrochlorothiazide | 148 | 48 |
| Zolpidem Tartrate | Zolpidem Tartrate | 146 | 29 |
| Doxycycline Hyclate | Doxycycline Hyclate | 145 | 89 |
| Jardiance | Empagliflozin | 136 | 21 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 134 | 40 |
| Buspirone Hcl | Buspirone Hcl | 131 | 34 |
| Fluoxetine Hcl | Fluoxetine Hcl | 131 | 34 |
| Prednisone | Prednisone | 130 | 89 |
| Xarelto | Rivaroxaban | 127 | 16 |
| Glimepiride | Glimepiride | 124 | 36 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 124 | 23 |
| Clopidogrel | Clopidogrel Bisulfate | 118 | 27 |
| Simvastatin | Simvastatin | 114 | 26 |
| Warfarin Sodium | Warfarin Sodium | 113 | 15 |
| Myrbetriq | Mirabegron | 109 | 15 |
| Azithromycin | Azithromycin | 108 | 85 |
| Allopurinol | Allopurinol | 105 | 33 |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 105 | 74 |
| Ropinirole Hcl | Ropinirole Hcl | 101 | 21 |
| Oxycodone Hcl | Oxycodone Hcl | 96 | 26 |
| Citalopram Hbr | Citalopram Hydrobromide | 94 | 24 |
| Pravastatin Sodium | Pravastatin Sodium | 92 | 26 |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 92 | 18 |
| Olanzapine | Olanzapine | 90 | 18 |
| Clonazepam | Clonazepam | 84 | 17 |
| Hydralazine Hcl | Hydralazine Hcl | 84 | 16 |
| Levetiracetam | Levetiracetam | 82 | 15 |
| Ondansetron Hcl | Ondansetron Hcl | 82 | 32 |
| Gemtesa | Vibegron | 81 | suppressed |
| Baclofen | Baclofen | 79 | 12 |
| Breo Ellipta | Fluticasone/Vilanterol | 77 | 12 |
| Bupropion Xl | Bupropion Hcl | 77 | 22 |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 76 | 16 |
| Alendronate Sodium | Alendronate Sodium | 75 | 19 |
| Diazepam | Diazepam | 74 | 15 |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 71 | 28 |
| Celecoxib | Celecoxib | 68 | 14 |
| Divalproex Sodium | Divalproex Sodium | 67 | 12 |
| Aripiprazole | Aripiprazole | 65 | 17 |
| Spironolactone | Spironolactone | 65 | 22 |
| Farxiga | Dapagliflozin Propanediol | 64 | 17 |
| Fluconazole | Fluconazole | 63 | 35 |
| Paroxetine Hcl | Paroxetine Hcl | 60 | 13 |
| Carbidopa-Levodopa | Carbidopa/Levodopa | 59 | 12 |
| Memantine Hcl | Memantine Hcl | 59 | 11 |
| Nystatin | Nystatin | 59 | 34 |
| Glipizide | Glipizide | 58 | 18 |
| Ipratropium-Albuterol | Ipratropium/Albuterol Sulfate | 58 | 30 |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 56 | 15 |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 56 | 41 |
| Amiodarone Hcl | Amiodarone Hcl | 55 | 12 |
| Finasteride | Finasteride | 55 | 12 |
| Nuedexta | Dextromethorphan Hbr/Quinidine | 53 | suppressed |
| Atenolol | Atenolol | 52 | 12 |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 52 | 40 |
| Mounjaro | Tirzepatide | 52 | 11 |
| Torsemide | Torsemide | 52 | 11 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 52 | 12 |
| Risperidone | Risperidone | 51 | 12 |
| Azelastine Hcl | Azelastine Hcl | 50 | 17 |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 50 | 16 |
| Ezetimibe | Ezetimibe | 49 | 12 |
| Oxcarbazepine | Oxcarbazepine | 49 | suppressed |
| Bupropion Hcl Sr | Bupropion Hcl | 48 | 12 |
| Cefadroxil | Cefadroxil | 48 | 45 |
| Valacyclovir | Valacyclovir Hcl | 48 | 20 |
| Lamotrigine | Lamotrigine | 47 | suppressed |
| Ondansetron Odt | Ondansetron | 47 | 34 |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 46 | 11 |
| Dextroamphetamine-Amphetamine | Dextroamphetamine/Amphetamine | 45 | suppressed |
| Naproxen | Naproxen | 44 | 25 |
| Entresto | Sacubitril/Valsartan | 43 | suppressed |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 43 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 42 | 13 |
| Donepezil Hcl | Donepezil Hcl | 42 | suppressed |
| Semglee (Yfgn) Pen | Insulin Glargine-Yfgn | 42 | suppressed |
| Diclofenac Sodium | Diclofenac Sodium | 41 | 26 |
| Benztropine Mesylate | Benztropine Mesylate | 40 | suppressed |
| Cephalexin | Cephalexin | 40 | 30 |
| Testosterone Cypionate | Testosterone Cypionate | 39 | suppressed |
| Benzonatate | Benzonatate | 37 | 29 |
| Levofloxacin | Levofloxacin | 37 | 33 |
| Morphine Sulfate Er | Morphine Sulfate | 37 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 37 | suppressed |
| Lovastatin | Lovastatin | 36 | suppressed |
| Permethrin | Permethrin | 36 | 31 |
| Sulfasalazine | Sulfasalazine | 36 | suppressed |
| Symbicort | Budesonide/Formoterol Fumarate | 36 | suppressed |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 35 | 32 |
| Sucralfate | Sucralfate | 35 | suppressed |
| Dicyclomine Hcl | Dicyclomine Hcl | 34 | 14 |
| Ozempic | Semaglutide | 34 | suppressed |
| Primidone | Primidone | 33 | suppressed |
| Bethanechol Chloride | Bethanechol Chloride | 32 | suppressed |
| Humalog Kwikpen U-100 | Insulin Lispro | 32 | suppressed |
| Terazosin Hcl | Terazosin Hcl | 32 | suppressed |
| Enalapril Maleate | Enalapril Maleate | 31 | suppressed |
| Loperamide | Loperamide Hcl | 30 | 11 |
| Oxybutynin Chloride | Oxybutynin Chloride | 30 | suppressed |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 28 | suppressed |
| Lacosamide | Lacosamide | 28 | suppressed |
| Calcium Acetate | Calcium Acetate | 27 | suppressed |
| Doxazosin Mesylate | Doxazosin Mesylate | 27 | suppressed |
| Morphine Sulfate | Morphine Sulfate | 27 | 13 |
| Januvia | Sitagliptin Phosphate | 26 | suppressed |
| Trulicity | Dulaglutide | 26 | suppressed |
| Amoxicillin | Amoxicillin | 25 | 20 |
| Ketoconazole | Ketoconazole | 25 | 15 |
| Methylprednisolone | Methylprednisolone | 25 | 21 |
| Mupirocin | Mupirocin | 25 | 16 |
| Chlorthalidone | Chlorthalidone | 24 | suppressed |
| Fenofibrate | Fenofibrate | 24 | suppressed |
| Insulin Aspart Flexpen | Insulin Aspart | 24 | 11 |
| Lithium Carbonate | Lithium Carbonate | 24 | suppressed |
| Midodrine Hcl | Midodrine Hcl | 24 | suppressed |
| Nifedipine Er | Nifedipine | 24 | suppressed |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 24 | suppressed |
| Tresiba Flextouch U-100 | Insulin Degludec | 24 | suppressed |
| Folic Acid | Folic Acid | 23 | suppressed |
| Glipizide Er | Glipizide | 23 | suppressed |
| Lansoprazole | Lansoprazole | 23 | suppressed |
| Lantus | Insulin Glargine,hum.Rec.Anlog | 23 | suppressed |
| Metronidazole | Metronidazole | 23 | 13 |
| Nano 2nd Gen Pen Needle | Pen Needle, Diabetic | 23 | suppressed |
| Nitrofurantoin | Nitrofurantoin Macrocrystal | 23 | suppressed |
| Nitroglycerin | Nitroglycerin | 23 | 15 |
| Anastrozole | Anastrozole | 22 | suppressed |
| Cyanocobalamin Injection | Cyanocobalamin (Vitamin B-12) | 22 | suppressed |
| Ibandronate Sodium | Ibandronate Sodium | 22 | suppressed |
| Insulin Lispro Kwikpen U-100 | Insulin Lispro | 22 | suppressed |
| Lidocaine | Lidocaine | 22 | suppressed |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 22 | suppressed |
| Pioglitazone Hcl | Pioglitazone Hcl | 22 | suppressed |
| Acetaminophen-Codeine | Acetaminophen With Codeine | 21 | suppressed |
| Anoro Ellipta | Umeclidinium Brm/Vilanterol Tr | 21 | suppressed |
| Cilostazol | Cilostazol | 21 | suppressed |
| Hydroxychloroquine Sulfate | Hydroxychloroquine Sulfate | 21 | suppressed |
| Linzess | Linaclotide | 21 | suppressed |
| Medroxyprogesterone Acetate | Medroxyprogesterone Acetate | 21 | suppressed |
| Testosterone | Testosterone | 21 | suppressed |
| Trintellix | Vortioxetine Hydrobromide | 21 | suppressed |
| Cefdinir | Cefdinir | 20 | 17 |
| Ceftriaxone | Ceftriaxone Sodium | 20 | suppressed |
| Clozapine | Clozapine | 20 | suppressed |
| Doxycycline Monohydrate | Doxycycline Monohydrate | 20 | 14 |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 20 | suppressed |
| Eszopiclone | Eszopiclone | 20 | suppressed |
| Labetalol Hcl | Labetalol Hcl | 20 | suppressed |
| Methotrexate | Methotrexate Sodium | 20 | suppressed |
| Mometasone Furoate | Mometasone Furoate | 20 | suppressed |
| Arexvy | Rsvpref3 Antigen/As01e/Pf | 19 | 19 |
| Brilinta | Ticagrelor | 19 | suppressed |
| Clotrimazole-Betamethasone | Clotrimazole/Betamethasone Dip | 19 | suppressed |
| Fiasp Flextouch | Insulin Aspart (Niacinamide) | 19 | suppressed |
| Ibuprofen | Ibuprofen | 19 | 11 |
| Latanoprost | Latanoprost | 19 | suppressed |
| Synthroid | Levothyroxine Sodium | 19 | suppressed |
| Ventolin Hfa | Albuterol Sulfate | 19 | 14 |
| Budesonide-Formoterol Fumarate | Budesonide/Formoterol Fumarate | 18 | suppressed |
| Carbidopa-Levodopa Er | Carbidopa/Levodopa | 18 | suppressed |
| Imipramine Hcl | Imipramine Hcl | 18 | suppressed |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 18 | suppressed |
| Santyl | Collagenase Clostridium Hist. | 18 | 14 |
| Vitamin D2 | Ergocalciferol (Vitamin D2) | 18 | suppressed |
| Bumetanide | Bumetanide | 17 | suppressed |
| Olmesartan-Hydrochlorothiazide | Olmesartan/Hydrochlorothiazide | 17 | suppressed |
| Oxycontin | Oxycodone Hcl | 17 | suppressed |
| Paliperidone Er | Paliperidone | 17 | suppressed |
| Pradaxa | Dabigatran Etexilate Mesylate | 17 | suppressed |
| Toujeo Solostar | Insulin Glargine,hum.Rec.Anlog | 17 | suppressed |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 16 | suppressed |
| Methimazole | Methimazole | 16 | suppressed |
| Namzaric | Memantine Hcl/Donepezil Hcl | 16 | suppressed |
| Spiriva Respimat | Tiotropium Bromide | 16 | suppressed |
| Sumatriptan Succinate | Sumatriptan Succinate | 16 | suppressed |
| Temazepam | Temazepam | 16 | suppressed |
| Vraylar | Cariprazine Hcl | 16 | suppressed |
| Benazepril Hcl | Benazepril Hcl | 15 | suppressed |
| Clonidine Hcl | Clonidine Hcl | 15 | suppressed |
| Hydroxyzine Pamoate | Hydroxyzine Pamoate | 15 | suppressed |
| Prednisolone Acetate | Prednisolone Acetate | 15 | suppressed |
| Topiramate | Topiramate | 15 | suppressed |
| Valsartan | Valsartan | 15 | suppressed |
| Diltiazem Hcl | Diltiazem Hcl | 14 | suppressed |
| Lidocaine-Prilocaine | Lidocaine/Prilocaine | 14 | suppressed |
| Nebivolol Hcl | Nebivolol Hcl | 14 | suppressed |
| Restasis | Cyclosporine | 14 | suppressed |
| Ultra-Fine Short Pen Needle | Pen Needle, Diabetic | 14 | suppressed |
| Verapamil Sr | Verapamil Hcl | 14 | suppressed |
| Cefpodoxime Proxetil | Cefpodoxime Proxetil | 13 | suppressed |
| Humira(Cf) | Adalimumab | 13 | suppressed |
| Incruse Ellipta | Umeclidinium Bromide | 13 | suppressed |
| Nyamyc | Nystatin | 13 | suppressed |
| Phenytoin Sodium Extended | Phenytoin Sodium Extended | 13 | suppressed |
| Varenicline Tartrate | Varenicline Tartrate | 13 | suppressed |
| Biktarvy | Bictegrav/Emtricit/Tenofov Ala | 12 | suppressed |
| Breztri Aerosphere | Budesonide/Glycopyr/Formoterol | 12 | suppressed |
| Clobetasol Propionate | Clobetasol Propionate | 12 | suppressed |
| Combivent Respimat | Ipratropium/Albuterol Sulfate | 12 | suppressed |
| Estradiol | Estradiol | 12 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 12 | suppressed |
| Phenobarbital | Phenobarbital | 12 | suppressed |
| Rizatriptan | Rizatriptan Benzoate | 12 | suppressed |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 12 | suppressed |
| Zolpidem Tartrate Er | Zolpidem Tartrate | 12 | suppressed |
| Dexlansoprazole Dr | Dexlansoprazole | 11 | suppressed |
| Digoxin | Digoxin | 11 | suppressed |
| Fluocinonide | Fluocinonide | 11 | suppressed |
| Humalog Junior Kwikpen | Insulin Lispro | 11 | suppressed |
| Metoclopramide Hcl | Metoclopramide Hcl | 11 | suppressed |
| Nortriptyline Hcl | Nortriptyline Hcl | 11 | suppressed |
| Wixela Inhub | Fluticasone Propion/Salmeterol | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $498.07 · 37 records | ABBVIE INC. | ELIQUIS, FREESTYLE LIBRE 3, GEMTESA, QULIPTA, The Cologuard Plus Collection Kit, UBRELVY, VRAYLAR, Wegovy, YUPELRI, ZORYVE | 6 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Eliquis play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error